Introduction
In type 1 diabetes (T1D), insulin producing b cells of the endocrine pancreas are destroyed by an autoimmune attack [1] . Exogenous insulin administration is necessary to control glycemia, but it cannot replace the highly specialized work done by b cells. As a matter of fact, patients with diabetes face two-sided complications: chronic risk of hyper and hypo-glycemia with correlated risks and long term complications due to the toxic effect of hyperglycemia on brain, nerves, vessels and heart [2] . Restoring the functional b cell mass is a possibility; this is an especially attractive case in cell therapy field because only a single cell type is missing and replacement can occur in non-endogenous sites. This has been extensively demonstrated by whole pancreas or pancreatic islet transplantation procedures as b cell replacement frequently results in euglycemia, but even partial function is able to reduce the risk of severe hypoglycemic events and limit the progression of diabetic complications [3, 4] . Despite its effectiveness, this therapy is still limited to a small number of patients with T1D, due to the unavailability of sufficient numbers of organs for transplantation and the difficulty of safely controlling rejection and autoimmunity with immunosuppressant drugs.
In this review we will focus on the possibility to use pluripotent stem cells to overcome the limits of islet transplantation and widen the application of cell replacement therapy to a large number of patients with T1D.
Pluripotent stem cells (ESC and iPSC) and ongoing clinical trials
To overcome the hurdles of islet transplantation, scientific community is currently focusing the attention on human pluripotent stem cells (PSC) as a source of functional b-like cells in vitro. As a matter of fact, in the field of in vitro differentiation from stem cells the most promising results have been achieved by using human embryonic stem cells (ESC) [5] or human induced pluripotent stem cells (iPSC) [6] . PSC are developmentally immature cells that have self-renewal abilities and hold the potential to become virtually any cell type of the body; indeed, PSC can be induced to undergo specific differentiation stages by exposure to defined combinations of stimuli to activate and/or inhibit signaling pathways to mimic, for instance, human pancreas development [7] . At first indeed the pioneering study of Novocell (now ViaCyte Inc.) focused on the discovery of the stimuli able to effectively specify ESC into cells of the definitive endoderm and subsequently in pancreatic progenitor cells up to insulin-producing cells, with an efficiency of 7% [8] . The group then dedicated to the efficient and large-scale production of proliferative and multipotent pancreatic progenitor cells, identified through co-expression of PDX1 and NKX6-1 [9] , following the evidence that, upon in vivo transplantation in murine models, a portion of these cells will spontaneously maturate into functional b-like cells [10] .
This strategy laid the foundation for the beginning of a prospective, multicenter, open-Label, First-in-Human Phase 1/2 clinical trial (ClinicalTrials.gov identifier: NCT02239354) in 2014 conducted by ViaCyte using a macro-encapsulated allogeneic hESC-derived pancreatic progenitor product (known as VC-01) in subjects with T1D. Next, in 2017, a new clinical trial was started (NCT03163511), testing ViaCyte's PEC-Direct product, a new open device allowing direct vascularization of pancreatic progenitor (PEC-01) cells but that requires immunosuppressant drugs, highlighting the presence of survival issues of encapsulated cells in human. Both these studies are ongoing and will certainly provide soon a great deal of information regarding a safe and effective use of stem cell-derived b cells in humans.
In the last 10 years, in parallel to the research on ESC, the study of induced pluripotent stem cells (iPSC) has increasingly taken the field. IPSC, derived from the genetic reprogramming of adult somatic cells [6] , have all the phenotypic/functional characteristics of ESC and several protocols of in vitro differentiation of iPSC into pancreatic b cells have been reported with encouraging results [11] [12] [13] . Human iPSC can be derived from healthy subjects but also from diabetic patients [14, 15 ] , therefore this kind of approach could lead to an autologous b cell replacement therapy. The translation of human iPSC to the clinical practice is already a reality in other fields [16] , as the first clinical study using human iPSC-derived retinal pigment epithelial (RPE) cells was initiated in 2014 in Japan for macular degeneration. The treatment proved to be safe and the transplanted tissue demonstrated engraftment and survival at 1 year from the transplant [17 ] , but the trial was subsequently put on hold due to the identification of two genetic variants in the iPSC of the second prospective patient [18] . The study was then redesigned and the first patient was treated March 28, 2017 [19] ; the strategy switched from an autologous to an allogeneic approach, with iPSC from a bank supplied by Kyoto University's Center for iPS Cell Research and Application.
Finally, two other clinical trials with iPSC have recently been approved: (i) allogeneic iPSC-derived mesenchymal stem cells (MSC) for Graft versus Host Disease (GvHD) in UK and Australia (NCT02923375) conducted by the Australian company Cynata Therapeutics and (ii) in Japan an allogeneic iPSC-based study for ischemic heart disease using sheets of cardiac cells to treat severe heart failure patients (Table 1) . These latest approved clinical trials highlight that scientific community, despite the feasibility of clinical development of an autologous hiPSCderived cell replacement product, is focusing on tuning an allogeneic iPSC therapy to minimize costs, time and quality controls of a personalized approach.
Differentiation efficiency, immunogenicity and safety are by now the main challenges that researchers have to face in order to facilitate the transition of PSC-derived b cells to patients with T1D [20 ] ( Figure 1 ).
In vitro and in vivo differentiation into b cells: efficacy
As reported, active clinical trials by ViaCyte are intended with ESC-derived pancreatic progenitors, as the efficient terminal in vitro differentiation into functional b cells comparable to those of adult human islets is still one of the main critical points. The process of b cell differentiation is orchestrated by fine-tuned transcriptional regulation of genes involved in pancreas development that depends on the type, number and timing of differentiation factors administrated and on the stem cell source and culture conditions. Over the last 10 years, multiple variations have been made to ViaCyte first protocol [8] , which was able to give rise to insulin-producing cells albeit nonresponsive to glucose stimuli. Modified or improved protocols have been established using combinations of cytokines and small molecules, such as many Fibroblast Growth Factors, Sonic hedgehog pathway inhibitors (KAAD-cyclopamine or SANT-1), Retinoic Acid, Nicotinamide, thyroid hormone, BMP inhibitors, protein kinase C activator (Indolactam V, PdBU), g-secretase inhibitors or TGFb pathway inhibitors (Alk5 inhibitor, Dorsomorphin or Noggin) [12, [21] [22] [23] . In two seminal papers [24, 25] , a novel and efficient approach to generate in vitro 20%-50% insulin (C-peptide)-positive cells from PSC was reported; differentiated cells resulted mono-hormonal and glucose responsive. Upon transplantation into immunocompromised mice, the graft (composed of endocrine and ductal cells) restored glycemia within 2 [24] or 6 weeks [25] after transplantation, a tremendous improvement compared to the 2-3 months period required for cell maturation after transplantation of ESC-derived pancreatic progenitor cells [10] . Similar results were obtained also by transplantation of iPSC-derived b cells, with human insulin detected in the sera of mice before and after glucose administration [13, 24] , even with iPSC derived from patients with T1D [15 ] .
The necessity to obtain insulin-positive cells with high efficiency has led, in addition to the identification of new molecules able to increase differentiation efficiency, to
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Immunogenicity of the graft
It is clear that PSCs offer a very powerful tool for the generation of new insulin producing cells, thanks to their intrinsic differentiation capacity and to the specific protocols of differentiation into b cells, which, as we have seen, have improved in the last years up to achieve very promising results. Several questions remain, however, that need to be addressed before these new b cells can be used in cell therapy in patients with diabetes. One of the major challenge is the immune rejection of PSC-derived cells by recipients. In fact, if one of the advantages of using iPSC in comparison to ESC is the possibility to use PSC reprogrammed from somatic cells of the patient who needs transplantation, it is true that this strategy has to face three main obstacles: (i) currently, a personalized therapy with autologous iPSC requires a huge economic and time commitment, (ii) the process of reprogramming leads to an elevated mutational load in iPSC [31, 32] , which could determine production of immunogenic proteins during forced differentiation into b cells, (iii) in diabetic patients, the new b cells, being autologous, could be attacked by a recurrence of the autoimmune response.
Therefore, whatever the source, ESC or allogeneic iPSC, but also autologous iPSC, the new b cells will still need to be protected by an attack of the recipient's immune system.
Immunosuppression:
The first possibility to protect the graft is to borrow the experience of allogeneic donor islet transplantation and use a lifetime immunosuppressive therapy [33] . It is likely that, in the case autologous iPSC are used, immunosuppressive therapy, aimed at avoiding only the autoimmune response, can be specifically modulated and can potentially be less toxic than standard therapy.
Encapsulation: Alternatively, the new b cells can be mechanically protected by placing a physical barrier between them and the cells of the immune system [34] . This approach, which has also been studied for years for islets from organ donors, is called encapsulation and can immuno-isolate one or few islets at times (microencapsulation), or all the transplanted b cells (macro-encapsulation). Encapsulation should provide immuno-protection to graft without the need for immunosuppressive drugs, in fact its goal is to avoid contact between b cells and immune system constituents of high molecular weight such as cells and antibodies, while at the same time allowing beneficial molecules such as hormones, oxygen and nutrients to pass the physical barrier. Stem cell therapies have led to an impulse in the field of micro-encapsulation research.
A first point to consider in order to apply microencapsulation for b cell transplantation is the bio-compatibility of the encapsulation material, which impacts on the correct functioning of the capsules. Indeed, a material that demonstrates perfect biocompatibility ensures that the capsules do not induce the formation of a strong fibrotic reaction. Various biomaterials have been proposed, starting from alginate and its advanced modifications, agarose, polyethylene glycol (PEG), poly-L-lysine (PLL) [35, 36] . An advantage of the microencapsulation strategy lies in the possibility to engineer the material used for encapsulation to release factors that dampen local inflammation and modulate the microenvironment of the graft in a cytoprotective manner; even the timing of in vivo release can be tuned according to the needs of the graft and the related microenvironment [37] .
However, despite the countless efforts and the promising results of allogeneic islets transplantation without systemic immune suppression, clinical trials with microencapsulated islets in humans until today have only proven safety, not long term efficacy. Recently, stimulated by the field of cell stem cell therapies, new studies have identified chemical modifications of alginate that increase capacity and biocompatibility. In particular, was reported the use of an alginate able to drastically limit the postimplant fibrotic reaction, inhibiting the response of tissue macrophages [38 ,39] . In addition, hopes are also placed in the conformal coating approach, which consists of minimizing capsule thicknesses so as to increase the exchange of nutrients and above all oxygen, thus potentially leading to a better outcome of transplantation [40] .
Macro-encapsulation: Also in this strategy, the development of suitable biomaterials is crucial and should satisfy the need for biocompatibility, durability, and perm selectivity [34, 41] . The immunoisolated islets commonly suffer from hypoxia and necrosis, which in turn triggers a host immune response. Oxygen transport across the capsule barrier is crucial for encapsulated islet survival and prevention of necrosis and therefore a balance must be found between allowing sufficient oxygen transfer while maintaining a barrier to immune cells and preventing rejection of the transplanted tissue. Efforts have been made to improve the supply of nutrients by using proangiogenic factors to augment the development of a vascular supply in the transplant site or by creating scaffolds that are in close proximity to a vascular network such as the omental blood supply [42] . One device in particular, named bAir, has adopted an approach in which oxygen is supplied to the implanted cells in an 'active' manner using an external system [43, 44] . It remains clear that inadequate oxygenation is a significant obstacle in the way of long-term graft success, with both micro-encapsulation and macroencapsulation. If successful, the encapsulation approach could be applied with any insulin-producing cell source, either organ donor, stem cells or other animal species such as pigs [45] .
Gene editing: One last strategy to evade immune rejection is based on the possibility to genetically modify the cells in such a way that they are no longer recognized by the cells of the immune system and therefore may evade post-implantation rejection. This approach has been accelerating in recent years for a twofold reason: (i) iPSC, unlike donor islets, can be effectively gene engineered as they can be expanded, cloned, sorted, and so on; (ii) the new CRISPR/ Cas9 methodologies have made gene targeting more feasible and selective. It has been recently shown in PSC that the deletion of B2M gene (a constituent of all the endogenous polymorphic HLA) coupled with the forced expression of the tolerogenic non-classical HLA-E molecule confers 'invisibility' to the cells, ensuring that they are neither attacked by T or NK cells [46 ] . Moreover, the ectopic expression of a modified form of HLA-G rendered PSC hypoimmunogenic [47] . Finally, also the disruption of T cell costimulatory pathways with cytotoxic T lymphocyte antigen 4 fused with immunoglobulin (CTLA4-Ig) and simultaneous activation of the T cell inhibitory pathway with programmed death ligand-1 (PD-L1) were able to confer immune protection [48] .
Safety of cell therapy with PSC
Finally, even if we overcome the challenges of increasing efficiency and avoiding rejection, we should nevertheless consider the potential risk of neoplastic transformation of the PSC derivatives. In fact, ESC and iPSC have a high tumorigenic potential because of their stemness and incomplete maturation during in vitro differentiation that can lead to pluripotent residual cells in the final cellular product. Furthermore, iPSC are cells strongly manipulated in vitro, both in the reprogramming phase and during expansion and differentiation. These manipulation steps increase the risk of uncontrolled proliferation and aberrant expression of proteins. Finally, in the case of the creation of invisible cells, unrecognized by the recipient's immune system, the risk is higher because the cell has been instructed to perform immuno-escape as a tumor cell.
To limit the tumorigenicity of these cells we should, when possible, (i) use the safest and latest generation reprogramming technique (non-integrative vectors, plasmids, RNA, and so on) and carefully monitor the cells for genomic instability (karyotype, aCGH); (ii) select only the desired cells after differentiation, eliminating unwanted residual pluripotent cells in the cellular preparation to be transplanted, and this can be obtained by negative selection of PSC [49, 50] or positive selection of endocrine cells with specific markers [26] [27] [28] [29] ; (iii) macro-encapsulate cells in a device that retains them and can be retrieved if necessary [34] ; (iv) introduce a suicide gene like TK or Casp9 that, when a specific drug is administered, activates and causes the cell to kill itself through apoptosis [51, 52] .
Conclusions
Pluripotent stem cells are starting to leave the lab and reach the test bench of clinical trials. Cell therapy with ESC is already in clinical trials for several diseases, including spinal cord injury, Parkinson disease, myocardial infarction and diabetes. To date, these first experiences showed a good safety profile, being the incidence of teratomas well controlled in all of the major clinical trials, and few, if any, adverse events reported. In terms of efficacy, the expectations are for the moment a bit resized, but only with the increase in the number of patients and the refinement of the protocols we will start to have more useful information.
Regarding iPSC, it is remarkable that only 10 years after discovering that somatic cells can be reprogrammed to pluripotency, the results of the first clinical study have been reported and clinical studies for a number of conditions, including diabetes, are on the horizon. However, translating these initial tests into routine and safe therapies for patients with diabetes requires a deep understanding of the potential and challenges.
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